​

Funding Round

Series A - Myricx Bio

Series A - Myricx Bio

Investment Firm

Overview

Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.

Announced Date

Jul 08, 2024

Closed on Date

Jul 08, 2024

Funding Type

Series A

Highlights

Location

Europe

Social

Investor Lead

Novo Holdings

Novo Holdings

Novo Holdings is a debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and secondary_market and seed and venture firm.

Abingworth

Abingworth

Abingworth is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

7

Investor Name
Participant InvestorSofinnova Partners
Participant InvestorAbingworth
Participant InvestorNovo Holdings
Participant InvestorEli Lilly
Participant InvestorBrandon Capital

Round Details and Background

Myricx Bio raised $115311437 on 2024-07-08 in Series A

Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Nov 16, 2020
Seed Round - Myricx Bio
2-5.9M
Jul 08, 2024
Series A - Myricx Bio
7-115.3M

Recent Activity

There is no recent news or activity for this profile.